US 11,719,696 B2
Methods and compounds for diagnosing threonyl-tRNA synthetase-associated diseases and conditions
Christopher Francklyn, Burlington, VT (US); Karen M. Lounsbury, Essex Junction, VT (US); and Tamara Williams, South Burlington, VT (US)
Assigned to The University of Vermont and State Agricultural College, Burlington, VT (US)
Filed by The University of Vermont and State Agricultural College, Burlington, VT (US)
Filed on Oct. 11, 2020, as Appl. No. 17/67,728.
Application 16/202,884 is a division of application No. 14/416,347, granted, now 10,175,237, issued on Jan. 8, 2019, previously published as PCT/US2013/051806, filed on Jul. 24, 2013.
Application 17/067,728 is a continuation of application No. 16/202,884, filed on Nov. 28, 2018, granted, now 11,340,227.
Claims priority of provisional application 61/675,652, filed on Jul. 25, 2012.
Prior Publication US 2021/0033611 A1, Feb. 4, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 33/573 (2006.01); C12Q 1/25 (2006.01); C12Q 1/6883 (2018.01); C12Q 1/6886 (2018.01); G01N 33/574 (2006.01)
CPC G01N 33/573 (2013.01) [C12Q 1/25 (2013.01); C12Q 1/6883 (2013.01); C12Q 1/6886 (2013.01); G01N 33/57496 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/9015 (2013.01); G01N 2800/52 (2013.01); G01N 2800/7014 (2013.01)] 20 Claims
 
1. A method of determining the onset, progression, or regression in a subject of a disorder associated with increased threonyl-tRNA synthetase (TARS) expression or activity, the method comprising:
(a) obtaining a first biological sample from a subject;
(b) measuring a level of a TARS molecule in the first biological sample;
(c) obtaining a second biological sample from the subject;
(d) measuring the level of the TARS molecule in the second biological sample obtained from the subject, wherein the second biological sample is obtained from the subject at a time subsequent to the time the first biological sample is obtained;
(e) comparing the measurement of the level of the TARS molecule in the first biological sample to the measurement of the level of the TARS molecule in the second biological sample as a determination of the onset, progression, or regression of the disorder associated with increased TARS activity, wherein an increase in the level of the TARS molecule in the second biological sample compared to the first biological sample indicates onset or progression of the disorder associated with increased TARS activity and a decrease in the level of the TARS molecule in the second biological sample compared to the first biological sample indicates regression of the disorder associated with increased TARS activity,
(f) selecting a treatment regimen for the subject based at least in part on the comparison of the level of the TARS molecule in first and second biological sample; and
(g) carrying out the selected treatment regimen in the subject.